Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Tigermed Consulting Co's quarterly market cap
declined
from Sep. 2025 (HK$39,401 Mil) to Dec. 2025 (HK$36,731 Mil) and
declined
from Dec. 2025 (HK$36,731 Mil) to Mar. 2026 (HK$35,681 Mil).
Hangzhou Tigermed Consulting Co's annual market cap
declined
from Dec. 2023 (HK$30,840 Mil) to Dec. 2024 (HK$26,640 Mil) but then
increased
from Dec. 2024 (HK$26,640 Mil) to Dec. 2025 (HK$36,731 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Hangzhou Tigermed Consulting Co's Enterprise Value for Today is HK$48,353 Mil.
Hangzhou Tigermed Consulting Co (HKSE:03347) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Hangzhou Tigermed Consulting Co Market Cap Related Terms
Hangzhou Tigermed Consulting Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:03347 vs TMO, DHR, IDXX: Market Cap Comparison
For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Tigermed Consulting Co Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Hangzhou Tigermed Consulting Co's Market Cap falls into.
Hangzhou Tigermed Consulting Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Tigermed Consulting Co (HKSE:03347) has a Market Cap of HK$44,683 Mil as of Jul. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hangzhou Tigermed Consulting Co and its competitors. According to the industry distribution chart, Hangzhou Tigermed Consulting Co ranks #25 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 11.5%.
Is Hangzhou Tigermed Consulting Co's Market Cap too high?
Hangzhou Tigermed Consulting Co's current Market Cap is HK$44,683 Mil. Based on the distribution chart, Hangzhou Tigermed Consulting Co ranks #25 out of 217 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Hangzhou Tigermed Consulting Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Tigermed Consulting Co's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Hangzhou Tigermed Consulting Co ranks #25 out of 217 companies for Market Cap. This places Hangzhou Tigermed Consulting Co in the top 12% of its industry — outperforming the majority of peers. The industry median Market Cap is 57.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 57.94, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hangzhou Tigermed Consulting Co and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 57.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Tigermed Consulting Co's current Market Cap is HK$44,683 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Tigermed Consulting Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co (HKSE:03347) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$49.30, compared to a current price of HK$37.20 — trading 24.5% below its estimated fair value. The current Market Cap is HK$44,683 Mil. Hangzhou Tigermed Consulting Co's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Hangzhou Tigermed Consulting Co (HKSE:03347), the current Market Cap is HK$44,683 Mil as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Tigermed Consulting Co (HKSE:03347) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be undervalued.
The current stock price of HK$37.20 is trading 24.5% below its estimated GF Value™ of HK$49.30.
GuruFocus considers Hangzhou Tigermed Consulting Co to be Modestly Undervalued.
Key valuation signals for HKSE:03347:
Market Cap: HK$44,683 Mil
GF Value™: HK$49.30 vs. price of HK$37.20 (24.5% below fair value)
No single metric tells the full story. See the HKSE:03347 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Tigermed Consulting Co Business Description
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
95GF Score
Get the complete analysis for HKSE:03347
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03347 has been successfully added to your 
